Avacta Group (LON:AVCT) Releases Earnings Results

Avacta Group (LON:AVCT) released its earnings results on Wednesday. The biotechnology company reported GBX (4.23) EPS for the quarter, Digital Look Earnings reports. Avacta Group had a negative return on equity of 1,293.07% and a negative net margin of 35,730.97%.

Avacta Group Stock Performance

Shares of Avacta Group stock remained flat at GBX 72 during trading hours on Friday. The stock had a trading volume of 612,341 shares, compared to its average volume of 1,710,805. The firm has a market capitalization of £337.35 million, a price-to-earnings ratio of -7.45 and a beta of 1.12. Avacta Group has a 52 week low of GBX 48 and a 52 week high of GBX 92. The company has a debt-to-equity ratio of 526.98, a current ratio of 0.95 and a quick ratio of 4.96. The business’s 50-day simple moving average is GBX 69.78 and its 200 day simple moving average is GBX 71.81.

About Avacta Group

Avacta Therapeutics is a clinical stage biopharmaceutical company challenging current drug delivery methods to expand the utility of highly potent cancer therapeutics.
The Company benefits from a world class research and development facility, team of exceptionally talented scientists and a highly experienced management team with members located in both the London headquarters and the US.

Our proprietary pre|CISION® platform masks toxic warheads by binding them to a short, engineered peptide that is cleavable only by the tumor-specific protease, fibroblast activation protein (FAP).